This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Delving into the data on amycretin in patients with obesity and diabetes which was presented at EASD 2024
Ticker(s): NVOWho's the expert?
Institution: UPMC
- Clinical Associate Professor of Medicine Clinical Unit Leader, Diabetes Multidisciplinary Unit UPMC Division of Endocrinology & Metabolism.
- Currently manages 150 patient with T2DM
- Familiar with the Phase 2a CTD for GSBR-1290 in individuals with both obesity and T2DM
Interview GoalTo discuss the current standard of care and the potential of Amycretin, an amylin and GLP-1 receptor agonist being developed by Novo Nordisk for weight loss and diabetes management.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
